CLINICAL PERFORMANCE OF HPV TESTING AND VIA IN PRIMARY, COMBINATION, AND SEQUENTIAL CERVICAL CANCER SCREENING IN CHINA.
WHO guidelines recommend screening with HPV testing followed by either treatment of all HPV positives, or by visual inspection (VIA) for triage to treatment, citing insufficient evidence to recommend either strategy over the other. We assessed VIA and HPV testing individually, in combination (HPV-VIA co-testing), and as triage models. 3,000 women were screened in Inner Mongolia, China, concurrently with HPV testing and VIA in a real population setting. Screen-positive women underwent colposcopy, and biopsy, if indicated. Accuracy of screening algorithms for cervical intraepithelial neoplasia grade 2 or higher (CIN-2+) was calculated after controlling for verification bias. HPV testing followed by VIA triage for CIN-2+ detection was compared to HC2 viral loads triage, measured in relative light units/cutoff (RLU/CO). CIN-2+ prevalence was 1·0%. Corrected sensitivity, false negative rate, and specificity for CIN-2+, respectively, for primary HPV testing were 89·7%, 10·3%, and 83·3%; 44·8%, 55·2%, and 92·3% for VIA; 93·1%, 6·9%, and 80·2% for HPV-VIA co-testing; and 41·4%, 58·6, and 95·4% for HPV with VIA triage scenarios. Using RLU/CO ≥5 to triage HPV-positive women had twice the sensitivity as VIA triage, with comparable specificity for CIN-2+. When VIA performs relatively poorly and HPV testing is available, adding VIA to sequential (i.e. HPV followed by VIA triage) or primary (HPV-VIA co-testing) screening does not significantly improve CIN-2+ detection beyond primary HPV screening alone. Sequential screening (i.e. HPV followed by VIA triage) reduces sensitivity too low for population-based screening programs. HPV viral loads could offer an alternative LRC triage strategy.